MXCT vs TMO
MXCT: MaxCyte enables cell therapy development through proprietary electroporation technology that delivers molecules into cells for engineering next-generation cell-based medicines. TMO: Thermo Fisher Scientific is a leading global provider of mission-critical laboratory equipment, analytical instrumentation, and scientific services for research and clinical markets.
Side-by-side fundamentals
| Metric | MXCT | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.14 | $526.46 | |
| Market cap as of 2026-07-23 | $125M | $194.1B | |
| P/E as of 2026-07-23 | n/a | 28.36 | |
| PEG as of 2026-07-23 | n/a | 2.89 | |
| Net margin as of 2026-07-23 | -121.2% | +15.2% | TMO higher |
| Gross margin as of 2026-07-23 | +80.5% | +40.9% | MXCT higher |
| Operating margin as of 2026-07-23 | -141.8% | +17.5% | TMO higher |
| ROE as of 2026-07-23 | -22.0% | +13.2% | TMO higher |
| ROA as of 2026-07-23 | -18.9% | +6.4% | TMO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.83 | MXCT lower |
| Revenue growth (YoY) as of 2026-07-23 | -14.3% | +5.4% | TMO higher |
| Revenue CAGR (3y) SEC XBRL | -9.3% | -0.3% | TMO higher |
| Dividend yield as of 2026-07-23 | n/a | +0.4% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.48 | 0.86 | |
| 1-year return as of 2026-07-22 close | -49.1% | +23.1% | TMO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.